menu search

UTHR / After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)

After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)
United Therapeutics (UTHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Read More
Posted: Jan 19 2023, 11:18
Author Name: Zacks Investment Research
Views: 111684

UTHR News  

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Dewey Steadman – He more_horizontal

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

By Zacks Investment Research
November 1, 2023

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

By Zacks Investment Research
November 1, 2023

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.38 per share, beating the Zacks Consensus Estimate of $4.89 per share. This compares more_horizontal

United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision

By Seeking Alpha
October 22, 2023

United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision

United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a com more_horizontal

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

By Seeking Alpha
August 3, 2023

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's finan more_horizontal

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it co more_horizontal

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.41 per share. This compares more_horizontal


Search within

Pages Search Results: